Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms

International Journal of Impotence Research volume 20, pages 145–149 (2008)Cite this article

Abstract

Erectile dysfunction is a prevalent disorder that not only affects men with the disorder but also their partners. Significant improvements in the sexual health of these couples have been achieved with the introduction of phosphodiesterase 5 (PDE5) inhibitors. Currently PDE5 inhibitors are used on an on-demand basis. New evidence regarding the effects of PDE5 inhibitors on the underlying pathophysiologic processes that cause erectile dysfunction have sparked interest in the continuous dosing of these medications. We will discuss the biological background and the available clinical evidence for the continuous use of phosphodiesterase inhibitors in erectile dysfunction. Lastly, we will discuss the emerging clinical data for the use of daily PDE5 inhibitors in men with lower urinary tract symptoms.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Selvin E, Burnett AL, Platz EA . Prevalence and risk factors for erectile dysfunction in the US. Am J Med 2007; 120: 151.

    Article  Google Scholar 

  2. Miller DC, Sanda MG, Dunn RL, Montie JE, Pimentel H, Sandler HM et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 2005; 23: 2772.

    Article  Google Scholar 

  3. Raina R, Lakin MM, Agarwal A, Mascha E, Montague DK, Klein E et al. Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy. Urology 2004; 63: 960.

    Article  Google Scholar 

  4. McMahon C . Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med 2004; 1: 292.

    Article  CAS  Google Scholar 

  5. Carson C, Shabsigh R, Segal S, Murphy A, Fredlund P, Kuepfer C et al. Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers. Urology 2005; 65: 353.

    Article  Google Scholar 

  6. Lue TF, Takamura T, Schmidt RA, Palubinskas AJ, Tanagho EA . Hemodynamics of erection in the monkey. J Urol 1983; 130: 1237.

    Article  CAS  Google Scholar 

  7. Wespes E, Goes PM, Schiffmann S, Depierreux M, Vanderhaeghen JJ, Schulman CC . Computerized analysis of smooth muscle fibers in potent and impotent patients. J Urol 1991; 146: 1015.

    Article  CAS  Google Scholar 

  8. De Young L, Bella A, Howard J, Brock G . Arteriogenic erectile dysfunction alters protein expression within the cavernosal tissue in an animal model. J Sex Med 2005; 2: 199.

    Article  CAS  Google Scholar 

  9. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J . Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990; 170: 843.

    Article  CAS  Google Scholar 

  10. Vernet D, Cai L, Garban H, Babbitt ML, Murray FT, Rajfer J et al. Reduction of penile nitric oxide synthase in diabetic BB/WORdp (type I) and BBZ/WORdp (type II) rats with erectile dysfunction. Endocrinology 1995; 136: 5709.

    Article  CAS  Google Scholar 

  11. Bivalacqua TJ, Usta MF, Champion HC, Adams D, Namara DB, Abdel-Mageed AB et al. Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats. J Urol 2003; 169: 1911.

    Article  CAS  Google Scholar 

  12. Saigal CS, Wessells H, Pace J, Schonlau M, Wilt TJ, Urologic Diseases in America Project. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med 2006; 166: 207.

    Article  Google Scholar 

  13. Salama N, Kagawa S . Ultra-structural changes in collagen of penile tunica albuginea in aged and diabetic rats. Int J Impot Res 1999; 11: 99.

    Article  CAS  Google Scholar 

  14. Jiang R, Chen JH, Jin J, Shen W, Li QM . Ultrastructural comparison of penile cavernous tissue between hypertensive and normotensive rats. Int J Impot Res 2005; 17: 417.

    Article  CAS  Google Scholar 

  15. Costa WS, Carrerete FB, Horta WG, Sampaio FJ . Comparative analysis of the penis corpora cavernosa in controls and patients with erectile dysfunction. BJU Int 2006; 97: 567.

    Article  Google Scholar 

  16. De Young L, Yu D, Freeman D, Brock GB . Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model. Int J Impot Res 2003; 15: 347.

    Article  CAS  Google Scholar 

  17. Ahn GJ, Yu JY, Choi SM, Kang KK, Ahn BO, Kwon JW et al. Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes. Int J Androl 2005; 28: 260.

    Article  CAS  Google Scholar 

  18. Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF . Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU Int 2006; 97: 625.

    Article  CAS  Google Scholar 

  19. Ferrini MG, Davila HH, Kovanecz I, Sanchez SP, Gonzalez-Cadavid NF, Rajfer J . Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology 2006; 68: 429.

    Article  Google Scholar 

  20. Ferrini MG, Kovanecz I, Sanchez S, Vernet D, Davila HH, Rajfer J et al. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. Biol Reprod 2007; 76: 915.

    Article  CAS  Google Scholar 

  21. Bivalacqua TJ, Usta MF, Champion HC, Leungwattanakij S, Dabisch PA, McNamara DB et al. Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats. Int J Impot Res 2004; 16: 21.

    Article  CAS  Google Scholar 

  22. DeBusk RF, Pepine CJ, Glasser DB, Shpilsky A, DeRiesthal H, Sweeney M . Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am J Cardiol 2004; 93: 147.

    Article  CAS  Google Scholar 

  23. Katz SD, Parker JD, Glasser DB, Bank AJ, Sherman N, Wang H et al. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. Am J Cardiol 2005; 95: 36.

    Article  CAS  Google Scholar 

  24. Musicki B, Champion HC, Becker RE, Kramer MF, Liu T, Sezen SF et al. In vivo analysis of chronic phosphodiesterase-5 inhibition with sildenafil in penile erectile tissues: no tachyphylaxis effect. J Urol 2005; 174: 1493.

    Article  CAS  Google Scholar 

  25. Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the prostate cancer outcomes study. JAMA 2000; 283: 354.

    Article  CAS  Google Scholar 

  26. Montorsi F, Guazzoni G, Strambi LF, Da Pozzo LF, Nava L, Barbieri L et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol 1997; 158: 1408.

    Article  CAS  Google Scholar 

  27. Kaplan SA, Gonzalez RR, Te AE . Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007; 51: 1717.

    Article  CAS  Google Scholar 

  28. Nandipati K, Raina R, Agarwal A, Zippe CD . Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections. Int J Impot Res 2006; 18: 446.

    Article  CAS  Google Scholar 

  29. Schwartz EJ, Wong P, Graydon RJ . Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol 2004; 171: 771.

    Article  Google Scholar 

  30. Carson CC, Hatzichristou DG, Carrier S, Lording D, Lyngdorf P, Aliotta P et al. Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. BJU Int 2004; 94: 1301.

    Article  CAS  Google Scholar 

  31. Mirone V, Costa P, Damber JE, Holmes S, Moncada I, Van Ahlen H et al. An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. Eur Urol 2005; 47: 846.

    Article  CAS  Google Scholar 

  32. Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC . Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998; 159: 1541.

    Article  CAS  Google Scholar 

  33. Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2006; 61: 280.

    Article  CAS  Google Scholar 

  34. Porst H, Giuliano F, Glina S, Ralph D, Casabe AR, Elion-Mboussa A et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006; 50: 351.

    Article  CAS  Google Scholar 

  35. Rajfer J, Aliotta PJ, Steidle CP, Fitch III WP, Zhao Y, Yu A . Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res 2007; 19: 95.

    Article  CAS  Google Scholar 

  36. McMahon C . Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005; 2: 415.

    Article  CAS  Google Scholar 

  37. McVary KT, Monnig W, Camps Jr JL, Young JM, Tseng LJ, van den Ende G . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007; 177: 1071.

    Article  CAS  Google Scholar 

  38. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401.

    Article  CAS  Google Scholar 

  39. Uckert S, Oelke M, Stief CG, Andersson KE, Jonas U, Hedlund P . Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 2006; 49: 740.

    Article  Google Scholar 

  40. Waldkirch ES, Uckert S, Langnase K, Richter K, Jonas U, Wolf G et al. Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol 2007; 52: 495.

    Article  CAS  Google Scholar 

  41. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007; 148: 1019.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Illinois at Chicago, Chicago, IL, USA

    H Pimentel & C Niederberger

  2. Department of Urology, University of Iowa, Iowa City, IA, USA

    M Wald

Authors
  1. H Pimentel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Wald
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Niederberger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Pimentel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pimentel, H., Wald, M. & Niederberger, C. Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms. Int J Impot Res 20, 145–149 (2008). https://doi.org/10.1038/sj.ijir.3901631

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901631

Keywords

Search

Advanced search

Quick links